Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Clinical and Research Reports   |    
Preliminary Study of the Association of White-Matter Metabolite Concentrations With Disease Severity in Patients With Huntington’s Disease
Jeffrey R. Yager, M.S.; Charles Gasparovic, Ph.D.; Vincent A. Magnotta, Ph.D.; William Adams, M.S.; Jess Fiedorowicz, M.D., Ph.D.; Jane Paulsen, Ph.D.; Ricardo Jorge, M.D.; Leigh J. Beglinger, Ph.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;26:101-104. doi:10.1176/appi.neuropsych.13020040
View Author and Article Information

From the Dept. of Radiology, University of Iowa, Iowa City, IA (JRY, VAM); The Mind Research Network, Albuquerque, NM (CG); Psychology Dept., University of New Mexico, Albuquerque, NM (CG); Dept. of Psychiatry, University of Iowa, Iowa City, IA (VAM, WA, JP, RJ, LJB); Dept. of Psychiatry, University of New Mexico, Albuquerque, NM (JF); and the Dept. of Epidemiology, University of Iowa, Iowa City, IA (JF).

Send correspondence to Jeffrey Yager; e-mail: jeffrey-yager@uiowa.edu

Copyright © 2014 by the American Psychiatric Association

Received February 25, 2013; Revised April 24, 2013; Accepted June 07, 2013.


Proton magnetic resonance spectroscopy is used to measure several metabolites in cortical gray and white matter in patients with Huntington’s disease. The preliminary results show that CAG-repeat length correlates with white-matter N-acetylaspartate concentrations, and disease severity correlates with several metabolites.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Anchor for Jump
TABLE 1.Pearson Correlation Coefficients (two-tailed p values)
Table Footer Note

N=6, except for Total Motor Score (TMS; N=5).

Table Footer Note

TFC: Total Functional Capacity; SDMT: Symbol Digit Modalities Test; TMTB: Trail-Making Test, Part B; GM: gray matter; WM: white matter; NAA: N-acetylaspartate; Cr: creatine; Cho: choline; Ins: myo-inositol.



Langbehn  DR;  Brinkman  RR;  Falush  D  et al; International Huntington’s Disease Collaborative Group:  A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length.  Clin Genet 2004; 65:267–277
[CrossRef] | [PubMed]
Aronin  N;  Chase  K;  Young  C  et al:  CAG expansion affects the expression of mutant Huntingtin in the Huntington’s disease brain.  Neuron 1995; 15:1193–1201
[CrossRef] | [PubMed]
Beglinger  LJ;  Nopoulos  PC;  Jorge  RE  et al:  White matter volume and cognitive dysfunction in early Huntington’s disease.  Cogn Behav Neurol 2005; 18:102–107
[CrossRef] | [PubMed]
Nopoulos  P;  Magnotta  VA;  Mikos  A  et al:  Morphology of the cerebral cortex in preclinical Huntington’s disease.  Am J Psychiatry 2007; 164:1428–1434
[CrossRef] | [PubMed]
Aylward  EH;  Codori  AM;  Rosenblatt  A  et al:  Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington’s disease.  Mov Disord 2000; 15:552–560
[CrossRef] | [PubMed]
Halliday  GM;  McRitchie  DA;  Macdonald  V  et al:  Regional specificity of brain atrophy in Huntington's disease.  Exp Neurol 1998;12:663–672
Magnotta  VA;  Kim  J;  Koscik  T  et al:  Diffusion tensor imaging in preclinical Huntington's disease.  Brain Imaging Behav 2009; 3:77–84
[CrossRef] | [PubMed]
Rosas  HD;  Tuch  DS;  Hevelone  ND  et al:  Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white-matter pathology and its relationship to clinical measures.  Mov Disord 2006; 21:1317–1325
[CrossRef] | [PubMed]
Sturrock  A;  Laule  C;  Decolongon  J  et al:  Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington’s disease.  Neurology 2010; 75:1702–1710
[CrossRef] | [PubMed]
Harms  L;  Meierkord  H;  Timm  G  et al:  Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study.  J Neurol Neurosurg Psychiatry 1997; 62:27–30
[CrossRef] | [PubMed]
Ferguson  KJ;  MacLullich  AM;  Marshall  I  et al:  Magnetic resonance spectroscopy and cognitive function in healthy elderly men.  Brain 2002; 125:2743–2749
[CrossRef] | [PubMed]
Dager  SR;  Corrigan  NM;  Richards  TL  et al:  Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders.  Top Magn Reson Imaging 2008; 19:81–96
[CrossRef] | [PubMed]
Gasparovic  C;  Neeb  H;  Feis  DL  et al:  Quantitative spectroscopic imaging with in situ measurements of tissue water T1, T2, and density.  Magn Reson Med 2009; 62:583–590
[CrossRef] | [PubMed]
Klöppel  S;  Draganski  B;  Golding  CV  et al:  White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington’s disease.  Brain 2008; 131:196–204
[CrossRef] | [PubMed]
Gu  X;  Li  C;  Wei  W  et al:  Pathological cell–cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 2005; 46:433–444
[CrossRef] | [PubMed]
References Container

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 4.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 10.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 10.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 52.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 5.  >
Topic Collections
Psychiatric News